Nflection Therapeutics
Boston, US · 9 employees on LinkedIn · 3 known investors
NFlection is a biopharmaceutical company developing novel therapeutics. The page does not state what the company's specific products or therapeutic focus are.
Founders & leadership
CP
Christopher PowalaChief Development Officer, Former President & CEO
MD
Mark de SouzainExecutive
Board
CG
Corey GoodmanBoard director
KP
Ketan PatelBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$44M disclosed across 3 rounds · 2016–2023
▶$4MraisedJul 2023 · 2 investors · BiotechnologyRule 506(b)
▶$4MraisedJul 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ketan PatelDirector
- Christopher PowalaDirector
- William HodderExecutive Officer, Director
- Corey GoodmanDirector
- Josh GrassDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedJun 2022 · 2 investors · BiotechnologyRule 506(b)
▶$20MraisedJun 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Corey GoodmanDirector
- William HodderExecutive Officer, Director
- Ketan PatelDirector
- Christopher PowalaDirector
- Josh GrassDirector
- Offering amount
- $30M
- Amount sold
- $20M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedApr 2020 · 2 investors · BiotechnologyRule 506(b)
▶$20MraisedApr 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Corey GoodmanDirector
- Christopher PowalaExecutive Officer, Director
- Ketan PatelDirector
- Mark de SouzaExecutive Officer, Director
- Offering amount
- $24M
- Amount sold
- $20M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Nflection Therapeutics do?
- NFlection is a biopharmaceutical company developing novel therapeutics. The page does not state what the company's specific products or therapeutic focus are.
- Who are Nflection Therapeutics's investors?
- Nflection Therapeutics's investors include F-Prime Capital, venBio Partners, venBio Global Strategic.
- How much funding has Nflection Therapeutics raised?
- Nflection Therapeutics has disclosed $44M raised across 3 rounds.
- Where is Nflection Therapeutics headquartered?
- Nflection Therapeutics is headquartered in Boston, US.